Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E ‐positive non–small cell lung cancer: A case report
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.14852 ↗Kurz gefasst
Fallbericht in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Yoshihiko Taniguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cerebral Infarction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Dabrafenib plus trametinib is the standard treatment for BRAF V600E ‐mutated non‐small cell lung cancer. No treatment‐related cerebral infarction (CI) has been reported in previous clinical trials. Here, we described a 61‐year‐old Japanese man with BRAF V600E ‐mutated lung adenocarcinoma treated with dabrafenib plus trametinib as a third‐line treatment. On the 10th day of dabrafenib plus trametinib treatment, the patient developed fever and was urgently hospitalized on the 18th day owing to impaired consciousness. The patient had disseminated intravascular coagulation because of infection, was treated with thrombomodulin and ceftriaxone, and subsequently improved. On the 44th day, dabrafenib plus trametinib was resumed with a one‐step dose reduction. Three hours after the first oral administration, the patient developed chills, fever, and hypotension. He received intravenous fluids. On the 64th day, 20 mg prednisolone was administered from the previous day, and dabrafenib plus trametinib was resumed with a further one‐step reduction in dose. Five hours after the first oral administration, the patient developed fever, hypotension, paralysis of the right upper and lower limbs, and dysarthria appeared. Head magnetic resonance imaging revealed multiple cerebral infarcts. Hemoconcentration because of intravascular dehydration may have caused CI. In conclusion, CI should be taken into consideration during treatment with dabrafenib plus trametinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.
- Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.
- Department of Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.
ORCID-Profile: Yoshihiko Taniguchi
Zitieren
APA
Taniguchi, Y., Tamiya, A., Yanagisawa, A., Shimaya, M., Kawakami, M., Inagaki, Y., Saijo, N., Matsuda, Y., & Okishio, K. (2023). Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E ‐positive non–small cell lung cancer: A case report. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14852
Vancouver
Taniguchi Y, Tamiya A, Yanagisawa A, Shimaya M, Kawakami M, Inagaki Y, et al. Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E ‐positive non–small cell lung cancer: A case report. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14852
BibTeX
@article{Taniguchi2023,
author = {Taniguchi, Yoshihiko and Tamiya, Akihiro and Yanagisawa, Atsushi and Shimaya, Minako and Kawakami, Mayu and Inagaki, Yuji and Saijo, Nobuhiko and Matsuda, Yoshinobu and Okishio, Kyoichi},
title = {Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E ‐positive non–small cell lung cancer: A case report},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.14852}
}
EUVIMED